Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
473 questions in 36 reviews · HIV/AIDS
current versionsNo studies 38 · 8%Ungraded 9 · 1.9%Very low 126 · 26.6%Low 127 · 26.8%Moderate 152 · 32.1%High 21 · 4.4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Multivitamins vs no multivitamins Birthweight Standard beam balance to nearest 10g · Pregnant and lactating women with HIV Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | no estimate extracted | 1 study · 800 participants | Moderate |
Intervention NR Preterm < 37 wks · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 1.1 [0.7, 1.76] | 1 study · 366 participants | Moderate |
Intervention NR Perinatal death · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 1.36 [0.75, 2.47] | 1 study · 397 participants | Moderate |
Intervention NR Birth weight (g) Standard balance beam to within 10g after birth · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | no estimate extracted | 1 study · 358 participants | Moderate |
Intervention NR Mean change in Log10viral load at 6 weeks postpartum PCR Roche Amplicor version 1.5kit · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | no estimate extracted | 1 study · 100 participants | Low |
Intervention NR Overall weight gain during pregnancy Calibrated balance beam scale to the nearest 100g · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | no estimate extracted | 1 study · 376 participants | Moderate |
Intervention NR Birth weight Standard mechanical scale to nearest 50g · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | no estimate extracted | 1 study · 842 participants | Moderate |
Intervention NR Low birth weight < 2500 g Standard mechanical scale to nearest 50g · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 0.68 [0.47, 0.98] | 1 study · 842 participants | Moderate |
Intervention NR Preterm birth < 37 weeks Gestational age was based on date of last menstrual period and was obtained at baseline · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 1.01 [0.74, 1.37] | 1 study · 842 participants | Moderate |
Intervention NR Perinatal death Death between 28 weeks gestation and 1 week after delivery · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 1.35 [0.85, 2.13] | 1 study · 881 participants | Moderate |
Intervention NR Progression to Hb < 8.6g/dL AcT Diff II Analyzer (Beckman Coulter) · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 0.63 [0.23, 1.73] | 1 study · 467 participants | Moderate |
Multivitamins vs no multivitamins Birth weight < 2500g Standard beam balance to nearest 10g · Pregnant and lactating women with HIV Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 0.55 [0.38, 0.81] | 1 study · 800 participants | Moderate |
Intervention NR Change in viral load · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | no estimate extracted | 438 participants | Ungraded |
Intervention NR Maternal mortality · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 1 [0.51, 1.97] | 1 study · 913 participants | Moderate |
Intervention NR Birth weight (grammes) Standard balance beam to nearest 10g · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | no estimate extracted | 1 study · 1000 participants | Moderate |
Intervention NR Birth weight < 2 500g Standard balance beam to nearest 10g · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 1.13 [0.79, 1.61] | 1 study · 1000 participants | Moderate |
Intervention NR Preterm birth < 37 weeks Gestational age based on the date of last menstrual period · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 1.04 [0.81, 1.35] | 1 study · 1030 participants | Moderate |
Intervention NR Small‐for‐gestational‐age Gestational age based on last menstrual period · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 1.24 [0.9, 1.71] | 1 study · 972 participants | Moderate |
Intervention NR Perinatal death · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 0.77 [0.48, 1.23] | 1 study · 1115 participants | Moderate |
Intervention NR Haemoglobin < 11g/dL within 10 weeks of delivery (dichotomous) CBC5 Coulter Counter · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 0.94 [0.67, 1.32] | 1 study · 272 participants | Low |
Intervention NR Mean viral load (log10) within 10 weeks of delivery Roche Amplicor HIV‐1 monitor test version 1.5 assay · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | no estimate extracted | 1 study · 174 participants | Low |
Multivitamins vs no multivitamins Preterm birth < 37 weeks Gestational age was determined using date of last menstrual period obtained at randomisation · Pregnant and lactating women with HIV Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 0.86 [0.68, 1.1] | 1 study · 888 participants | Moderate |
Multivitamins vs no multivitamins Small‐for‐gestational‐age Gestational age was determined using date of last menstrual period obtained at randomisation · Pregnant and lactating women with HIV Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 0.57 [0.4, 0.83] | 1 study · 768 participants | Moderate |
Multivitamins vs no multivitamins Foetal death (stillbirth and miscarriage) · Pregnant and lactating women with HIV Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 0.61 [0.39, 0.94] | 1 study · 1021 participants | Moderate |
Multivitamins vs no multivitamins Maternal change in mean Haemoglobin from baseline to 6 weeks post‐partum CBC5 Coulter Counter · Pregnant and lactating women with HIV Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | no estimate extracted | 1 study · 1021 participants | Moderate |
Multivitamins vs no multivitamins Maternal change in mean CD4 from baseline to 6 weeks post‐partum FACScount system (Becton‐Dickinson) · Pregnant and lactating women with HIV Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | no estimate extracted | 1 study · 516 participants | Low |
Intervention NR Mean change in Haemoglobin at 6 weeks post partum CBC5 Coulter Counter · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | no estimate extracted | 1 study · 357 participants | Moderate |
Intervention NR Low birth weight < 2500g Standard balance beam to within 10g after birth · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 1.06 [0.58, 1.93] | 1 study · 358 participants | Moderate |
Mobile phone text messages vs standard care Viral load suppression at 52 weeks · Patients with HIV infection, on ART Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection (2012) · Cochrane | RR 0.83 [0.69, 0.99] | 1 study · 538 participants | High |
Intervention NR ART adherence at 48 weeks: Weekly vs. daily messages (overall) · Patients with HIV infection, on ART Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection (2012) · Cochrane | RR 0.79 [0.64, 0.99] | 1 study · 289 participants | Low |
Intervention NR ART adherence at 48 weeks: Short vs. long messages (overall) · Patients with HIV infection, on ART Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection (2012) · Cochrane | RR 1.01 [0.81, 1.25] | 1 study · 289 participants | Low |
Intervention NR Very few events. · Patients with HIV infection, on ART Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection (2012) · Cochrane | no estimate extracted | 1 participants | Ungraded |
Mobile phone text messages vs standard care ART adherence at 48‐52 weeks: Text messages vs. standard care (overall) · Patients with HIV infection, on ART Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection (2012) · Cochrane | RR 0.82 [0.72, 0.94] | 2 studies · 966 participants | High |
Mobile phone text messages vs standard care ART adherence at 48‐52 weeks: Weekly text messages vs. standard care (overall) · Patients with HIV infection, on ART Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection (2012) · Cochrane | RR 0.78 [0.68, 0.89] | 2 studies · 898 participants | High |
Mobile phone text messages vs standard care ART adherence at 48‐52 weeks: Short weekly messages vs. standard care · Patients with HIV infection, on ART Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection (2012) · Cochrane | RR 0.77 [0.66, 0.9] | 2 studies · 750 participants | High |
Mobile phone text messages vs standard care ART adherence at 48 weeks: Long weekly messages vs. standard care · Patients with HIV infection, on ART Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection (2012) · Cochrane | RR 0.79 [0.6, 1.04] | 1 study · 213 participants | Low |
Mobile phone text messages vs standard care ART adherence at 48 weeks: Short daily messages vs. standard care · Patients with HIV infection, on ART Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection (2012) · Cochrane | RR 1 [0.79, 1.27] | 1 study · 209 participants | Low |
Mobile phone text messages vs standard care ART adherence at 48 weeks: Long daily messages vs. standard care · Patients with HIV infection, on ART Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection (2012) · Cochrane | RR 0.98 [0.77, 1.24] | 1 study · 211 participants | Low |
Mobile phone text messages vs standard care Very few events. · Patients with HIV infection, on ART Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection (2012) · Cochrane | no estimate extracted | 1 participants | Ungraded |
Intervention NR ART adherence at 48 weeks: Short weekly messages vs. long weekly messages · Patients with HIV infection, on ART Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection (2012) · Cochrane | RR 0.98 [0.7, 1.39] | 1 study · 147 participants | Low |
Topical thalidomide vs Another topical agent or placebo Adverse effects of long‐term use of available topical agents · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers Topical treatments for HIV‐related oral ulcers (2012) · Cochrane | No studies were included in this review. A total of 233 abstracts were retrieved; 25 were selected as potentially eligible but all were excluded (10 reported systemic rather than topical treatment; 3 non‐RCTs; 6… | 0 studies | No studies |
HAART regimen + topical treatment vs HAART regimen alone Pain relief · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers Topical treatments for HIV‐related oral ulcers (2012) · Cochrane | No studies were included in this review. A total of 233 abstracts were retrieved; 25 were selected as potentially eligible but all were excluded (10 reported systemic rather than topical treatment; 3 non‐RCTs; 6… | 0 studies | No studies |
HAART regimen + topical treatment vs HAART regimen alone Incidence and recurrence after healing of ulcers · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers Topical treatments for HIV‐related oral ulcers (2012) · Cochrane | No studies were included in this review. A total of 233 abstracts were retrieved; 25 were selected as potentially eligible but all were excluded (10 reported systemic rather than topical treatment; 3 non‐RCTs; 6… | 0 studies | No studies |
Antiseptic mouthwash (e.g. chlorhexidine) vs Another topical agent or placebo Adverse effects of long‐term use of available topical agents · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers Topical treatments for HIV‐related oral ulcers (2012) · Cochrane | No studies were included in this review. A total of 233 abstracts were retrieved; 25 were selected as potentially eligible but all were excluded (10 reported systemic rather than topical treatment; 3 non‐RCTs; 6… | 0 studies | No studies |
Topical thalidomide vs Another topical agent or placebo Healing of ulceration · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers Topical treatments for HIV‐related oral ulcers (2012) · Cochrane | No studies were included in this review. A total of 233 abstracts were retrieved; 25 were selected as potentially eligible but all were excluded (10 reported systemic rather than topical treatment; 3 non‐RCTs; 6… | 0 studies | No studies |
Topical thalidomide vs Another topical agent or placebo Duration to heal oral ulcerations after initiation of treatment · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers Topical treatments for HIV‐related oral ulcers (2012) · Cochrane | No studies were included in this review. A total of 233 abstracts were retrieved; 25 were selected as potentially eligible but all were excluded (10 reported systemic rather than topical treatment; 3 non‐RCTs; 6… | 0 studies | No studies |
Recombinant Human Erythropoietin vs Placebo Death · patients with anemia in people with AIDS Treatment for anemia in people with AIDS (2011) · Cochrane | RR 0.56 [0.08, 4.05] | 2 studies · 84 participants | Very low |
On site voluntary testing and counselling vs Voucher Uptake of testing · patients with uptake of HIV testing Interventions to reduce risky sexual behaviour for preventing HIV infection in workers in occupational… (2011) · Cochrane | RR 14 [11.75, 16.68] | 1 study · 7482 participants | Moderate |
Theory based education vs alternative education Number of sex partners varying questions. Scale from: 0 to 20. · patients with reducing risky sexual behaviour Interventions to reduce risky sexual behaviour for preventing HIV infection in workers in occupational… (2011) · Cochrane | no estimate extracted | 3 studies · 1048 participants | Ungraded |
Behavioural intervention vs control STI incidence for sex workers · Sex workers and their clients Behavioral interventions to reduce the transmission of HIV infection among sex workers and their clients in… (2011) · Cochrane | RR 0.46 [0.11, 1.98] | 2 studies · 627 participants | Very low |